Summary of all MiYOSMART studies

The increasing prevalence of myopia in children is a topic that has gained a high level of attention among many, especially the parents of myopic children. By recommending MiYOSMART spectacle lens, you are following an innovative1 and evidence-based myopia management. Here you can find a summary of all the studies involving MiYOSMART to date.


Our research partner: The Hong Kong Polytechnic University

HOYA Vision Care has been working in close partnership with the Centre for Myopia Research at The Hong Kong Polytechnic University for many years. Together, we developed the innovative1 D.I.M.S. Technology which forms  the basis MiYOSMART spectacle lenses for myopia management.


The Hong Kong Polytechnic University has an excellent reputation in the scientific field, with over 30 years of experience in myopia research. It is also one of the Top 100 universities worldwide.2 Six of their scientists are listed among the 200 internationally leading myopia researchers.3 In 2002, Professor Chi Ho To and Professor Carly Siu Yin Lam and their research team developed the defocus incorporated soft contact (DISC) lens, one of the pioneering products for myopia control selling across China.4




The fundamentals: the peripheral defocus theory

The peripheral defocus theory is the current, internationally accepted theory for explaining induced myopia progression due to the usage of single vision spectacle lenses. This theory is based on various animal and human studies, which confirm that peripheral hyperopic  defocus increases myopia progression and thus supports peripheral myopic defocus as a treatment option.5


The peripheral defocus theory is supported  by leading researchers in the guidance from the European Ophthalmological Society6 and in the International Myopia Institute (IMI) White Paper, IMI - Report on Experimental Models of Emmetropization and Myopia.6,7


Further reading and summaries of the IMI White Papers, as well as their translations into various languages, can be found on the IMI website.8


Current MiYOSMART research: scientific evidence for effectiveness and safety

The Hong Kong Polytechnic University carried out two studies demonstrating the efficacy9 and effectiveness10 of MiYOSMART spectacle lenses: a 2-year, randomised double-blind study and a 3-year follow-up study, which were published in  the reputable British Journal of Ophthalmology. These studies are open to the public, so everyone can access the research.


Subsequently, the data from the 6-year follow-up study was presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting in 2022 held in Denver, USA. The data showed that over six years, the control effect was sustained and there was no rebound effect in the children who stopped wearing MiYOSMART.11


Further studies verified different aspects of MiYOSMART spectacle lens performance such as tolerability, safety and optical properties:


Myopia control options: MiYOSMART comparison with other myopia management solutions

Two papers published in 2021, Efficacy in myopia control17 and Myopia treatment and  prophylaxis with defocus incorporated multiple segments spectacle lenses18 discuss the effectiveness of MiYOSMART compared with other options in myopia management. While a recent study from 2022 shows the synergistic effect when MiYOSMART is combined with atropine19.

Conclusion: MiYOSMART is a safe and effective method of myopia management in children9-11

More than two million MiYOSMART spectacle lenses have been sold across the world with the innovative1 D.I.M.S. Technology.20 The currently published research results from the various sources support MiYOSMART as an effective method for slowing down myopia progression.9-11

Further clinical studies are currently running. As soon as results are published, we will update our MiYOSMART related materials and inform you.

Learn More About MiYOSMART

Disclaimer: MiYOSMART is not approved for myopia management in all countries, including the United States, and is not currently available for sale in all countries, including  the United States.



1.     Patent protected in China (ZL 201310628174.8), Hong Kong (1210838), and the United States (10268050 & 11029540).

2.     The Hong Kong Polytechnic University. QS World University Rankings. 2023. Available from: (Last accessed: 04/01/2023)

3.     Six PolyU researchers ranked in the Top 200 in optometry. The Hong Kong Polytechnic University. April 2021. Available from: (Last accessed: 04/01/2023)

4.     Lam CS, Tang WC, Tse DY, Tang YY, To CH. Defocus Incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial. Br J Ophthalmol. 2014;98(1):40-5. doi:10.1136/bjophthalmol-2013-303914

5.     Berntsen DA, Barr CD, Mutti DO, Zadnik K. Peripheral defocus and myopia progression in myopic children randomly assigned to wear single vision and progressive addition lenses. Invest Ophthalmol Vis Sci. 2013;54(8):5761-70. doi:10.1167/iovs.13-11904.

6.     Németh J, Tapasztó B, Aclimandos WA, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021;31(3):853-883. doi:10.1177/1120672121998960.

7.     Troilo D, Smith EL 3rd, Nickla DL, et al. IMI - Report on Experimental Models of Emmetropization and Myopia. Invest Ophthalmol Vis Sci. 2019;60(3):M31-M88. doi:10.1167/iovs.18-25967

8.     IMI White Papers & Clinical Summaries. International Myopia Institute. 2023. Available from: (Last accessed: 04/01/2023)

9.     Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368. doi:10.1136/bjophthalmol-2018-313739

10.  Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. Br J Ophthalmol. 2022;106(8):1110-1114. doi:10.1136/bjophthalmol-2020-317664

11.  Lam CSY, Tang WC, Zhang A, Tse D, To CH. Myopia control in children wearing DIMS spectacle lens: 6 years results (Abstract). Invest Ophthalmol Vis Sci. 2022;63(7):4247. Available from: (Last accessed: 04/01/2023)

12.  Lu Y, Lin Z, Wen L, et al. The Adaptation and Acceptance of Defocus Incorporated Multiple Segment Lens for Chinese Children. Am J Ophthalmol. 2020;211:207-216. doi:10.1016/j.ajo.2019.12.002

13.  Jaskulski M, Singh NK, Bradley A, Kollbaum PS. Optical and imaging properties of a novel multi-segment spectacle lens designed to slow myopia progression. Ophthalmic Physiol Opt. 2020;40(5):549-556. doi:10.1111/opo.12725

14.  Kaymak H, Neller K, Schütz S, et al. Vision tests on spectacle lenses and contact lenses for optical myopia correction: a pilot study. BMJ Open Ophthalmol. 2022;7(1):e000971. Published 2022 Apr 5. doi:10.1136/bmjophth-2022-000971

15.  Kaymak H, Mattern AI, Graff B, et al. Safety of DIMS Spectacle Lenses and Atropine as Combination Therapy for Myopia Progression. Sicherheit von Brillengläsern mit DIMS-Technologie und Atropin in der Kombinationstherapie der Myopieprogression. Klin Monbl Augenheilkd. 2022;239(10):1197-1205. doi:10.1055/a-1930-7116.

16.  Kaymak H. Controlling the growing problem of myopia in children. November 2022. Available from: (Last accessed: 04/01/2023)

17.  Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923. doi:10.1016/j.preteyeres.2020.100923

18.  Kaymak H, Graff B, Neller K, Langenbucher A, Seitz B, Schwahn H. Myopietherapie und Prophylaxe mit „Defocus Incorporated Multiple Segments“-Brillengläsern [Myopia treatment and prophylaxis with defocus incorporated multiple segments spectacle lenses]. Ophthalmologe. 2021 Dec;118(12):1280-1286. German. doi: 10.1007/s00347-021-01452-y.

19.  Huang, Z., Chen, XF., He, T. et al. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep 12, 22311 (2022).

20.  Based on number of MiYOSMART lenses sold per Hoya sales data on file as of June 2022.

About HOYA Vision Care

For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high quality, high performing eyeglass lenses, HOYA continues to drive optical technology innovation with the aim of finding the best vision care solutions for Eye Care Professionals. The company supplies lenses in 52 countries with a network of over 18,000 employees and 45 laboratories around the globe.

About Hoya